In the current study, we overexpressed TMEM166 in low-expressing HCC cells and deleted it in high-expressing HCC cells and found that TMEM166 negatively regulate UPR to inhibit HCC progression and increase sorafenib sensitivity. Here, EVA1A is linked to hepatocellular carcinoma.